Maria de Lourdes Barbosa-Cortes

Dr. Maria de Lourdes Barbosa-Cortes

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
MLMardia López-Alarcón
Mardia López-Alarcón
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
MKMiguel Klunder-Klunder
Miguel Klunder-Klunder
MRMaría del Carmen Rodríguez-Zepeda
María del Carmen Rodríguez-Zepeda
RBRoberto Bernaldez-Rios
Roberto Bernaldez-Rios
There is a growing body of evidence indicating that pediatric survivors of cancer are at a greater risk of developing metabolic syndrome. This study evaluated some probable predictors of metabolic syndrome (MS), such as leptin and adiponectin concentrations, the leptin/adiponectin ratio, insulin resistance, and adiposity, in a sample of child survivors of lymphoma and leukemia in Mexico City. Fifty two children (leukemia n = 26, lymphoma n = 26), who were within the first 5 years after cessation of therapy, were considered as eligible to participate in the study. Testing included fasting insulin, glucose, adipokines and lipids; body fat mass was measured by DXA. The MS components were analyzed according to tertiles of adipokines, insulin resistance, and adiposity. Comparisons between continuous variables were performed according to the data distribution. The MS components were analyzed according to tertiles of adipokines, insulin resistance, and adiposity. With the purpose of assessing the risk of a present MS diagnosis, odds ratios (OR) with a 95% confidence interval (95% IC) were obtained using logistic regression analysis according to the various metabolic markers. The median children age was 12.1 years, and the interval time from the completion of therapy to study enrollment was 4 years. Among the MS components, the prevalence of HDL-C low was most common (42%), followed by central obesity (29%). The HOMA-IR (OR 9.0, 95% CI 2.0; 41.1), body fat (OR 5.5, 95% CI 1.6; 19.3), leptin level (OR 5.7, 95% CI 1.6; 20.2) and leptin/adiponectin ratio (OR 9.4, 95% CI 2.0; 49.8) in the highest tertile, were predictive factors of developing MS; whereas the lowest tertile of adiponectin was associated with a protective effect but not significant. Biomarkers such as HOMA-IR, leptin and leptin/adiponectin are associated with each of the components of the MS and with a heightened risk of suffering MS among children survivors of cancer. Given the close relationship between MS with risk of developing type 2 diabetes and cardiovascular disease, it is imperative to implement prevention measures in this population and especially in developing countries where these pathologies have become the leading cause of death.

31 March 2005 in Nutrition
Verified
Journal Article
Closed access
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
HVHerlinda Vera
Herlinda Vera
SMSegundo Moran
Segundo Moran
MPMartha Del Prado
Martha Del Prado
MLMardya López-Alarcón
Mardya López-Alarcón

12 July 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
XMXimena Martínez-Vieyra
Ximena Martínez-Vieyra
JMJuan Manuel Mejía-Aranguré
Juan Manuel Mejía-Aranguré
MLMardia López-Alarcón
Mardia López-Alarcón
JMJorge Martin-Trejo
Jorge Martin-Trejo
RPRuy Xavier Pérez-Casillas
Ruy Xavier Pérez-Casillas

14 April 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
JMJorge Alfonso Martin-Trejo
Jorge Alfonso Martin-Trejo
EJEmmanuel Jiménez-Aguayo
Emmanuel Jiménez-Aguayo
FMFabian Ismael Martínez-Becerril
Fabian Ismael Martínez-Becerril
RPRuy X. Pérez-Casillas
Ruy X. Pérez-Casillas
Introduction: Increased triglycerides (TGs) are a major risk factor for cardiovascular disease. Furthermore, hypertriglyceridemia is commonly associated with a reduction of high-density lipoprotein cholesterol (HDL-C) and an increase in atherogenic small-dense low-density lipoprotein (LDL-C) levels. Studies provide support that polyunsaturated omega-3 fatty acids (ω3-LCPUFAs) are cardioprotective and have antithrombotic and anti-inflammatory effects. The potential effects of ω3-LCPUFAs on cardiometabolic factors and anti-inflammatory actions in children with acute lymphoblastic leukemia (ALL) are limited. This is a secondary analysis of a previous clinical trial registered at clinical trials.gov (# NCT01051154) that was conducted to analyze the effect of ω3-LCPUFAs in pediatric patients with ALL who were receiving treatment.Objective: To examine the effect of supplementation with ω3-LCPUFAs on cardiometabolic factors in children with ALL undergoing treatment.Methods: Thirty-four children (placebo group: 20 patients; ω3-LCPUFAs group: 14 patients) aged 6.7 ± 2.7 years who were newly diagnosed with ALL were evaluated. Children were randomized to receive either ω3-LCPUFAs or placebo capsules (sunflower oil). ω3-LCPUFAs were administered in the form of 500-mg soft capsules. The ω3-LCPUFA capsules contained 225 mg of DHA, 45 mg of EPA, and 20 mg of another ω3-LCPUFAs. The omega-3 dose was administered at a rate of 0.100 g/kg of body weight/day for three months. Main outcomes: Fasting cholesterol, HDL-C, very-low-density lipoprotein (VLDL-C), TGs, atherogenic index of plasma (AIP), android/gynoid ratio (A/GR), IL-6, TNF-α, and percentage of fat mass (DXA) were measured in all patients. Fatty acid analyses in red blood cells were performed with gas chromatography.Results: We found significantly lower levels of TGs (p=0.043), VLDL-C (p=0.039), IL-6 (p=0.025), and AIP (p=0.042) in the ω3-LCPUFAs group than in the placebo group at three months. In contrast, the total cholesterol concentration was higher at 3 months in the ω3-LCPUFAs group than in the placebo group (155 mg/dl vs. 129 mg/dl, p=0.009). The number of children with hypertriglyceridemia (85% vs. 50%; p=0.054) tended to be lower between the time of diagnosis and after 3 months of supplementation with ω3-LCPUFAs.Conclusion: These findings support the use of ω3-LCPUFAs to reduce some adverse cardiometabolic and inflammatory risk factors in children with ALL.Clinical trial registration: ClinicalTrials.gov, identifier NCT01051154.

1 October 2007 in Nutrition
Verified
Journal Article
Closed access
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
MTMarisa Tapia-Rojas
Marisa Tapia-Rojas
ELEnrique López-Aguilar
Enrique López-Aguilar
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
HRHugo Rivera-Márquez
Hugo Rivera-Márquez

14 June 2019 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
JZJessie Nallely Zurita-Cruz
Jessie Nallely Zurita-Cruz
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
MVMiguel Angel Villasis-Keever
Miguel Angel Villasis-Keever
Clinical trials become very relevant in the development of new drugs when their pharmacokinetics, pharmacodynamics, efficiency, safety and possible adverse effects are being assessed. So new drugs are available for their daily use in patients, a model has been proposed for more than four decades; This model consists in the realization of sequential research studies, which were called clinical phases I, II, III and IV, which begin once the drugs’ effects have been verified in cellular and animal models (preclinical phase). In this article, the general characteristics of each of the clinical phases are synthesized but, apart from that, the modifications that have been done over the years are described with the purpose of making new drugs available in a quicker way.